SIBIONICS Announces Participation in the 17th International Conference on Advanced Technologies and Treatments for Diabetes

Our Bureau

SIBIONICS, the world’s third-largest continuous glucose monitoring (CGM) brand, announced that it will participate in the International Diabetes Technology Exhibition at the 17th Symposium on Diabetes at the 17th Symposium on Diabetese International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy, March 6-9, 2024. It will be showcasing its latest CGM solutions for diabetes management at booth no 15. SIBIONICS claims to have worked with more than 1,800 hospitals to integrate the CGM system into inpatient treatment, benefiting more than 850,000 people worldwide in their diabetes management. SIBIONICS is building an automated production line with an annual capacity of 18 million CGM systems, which is expected to be completed in 2024.

Having received the CE mark for medical devices in October 2023, SIBIONICS’ CGM system entered the European market in November. Due to the strong capabilities of its products and positive user feedback, SIBIONICS has rapidly expanded its global partnerships. In 2024, driven by its commitment to customer-centric innovation, SIBIONICS is investing in collaboration with users to develop a CGM solution that precisely aligns with their needs. In addition to type 1 diabetes, the commitment encompasses type 2 diabetes, prediabetes and metabolic disorders. With a focus on the importance of blood glucose management, SIBIONICS aims to offer comprehensive, high-quality diabetes treatment solutions to improve overall health.

During the ATTD Conference, the company will host an exhilarating brand event titled “SIBIONICS Influencer Talk: Realizing the Unimagined” on March 9, 2024, where healthcare professionals, dietitians, and thought leaders in the field of diabetes management will come together to discuss in detail the tremendous potential of CGM system technology and its critical role in creating solutions future diabetes management.

The “SIBIONICS Influencer Talk: Realizing the Unimagined” event will include engaging discussions on the company’s upcoming launch plans for the new GS1 – GS2, Reusable Transmitter – GS ECO continuous glucose monitoring versions and for the continuous combined glucose and ketone level measurement system, thought-provoking presentations and interactive Q&A sessions, that will create a dynamic atmosphere conducive to co-developed diabetes management solutions with users.

This important and exciting event will take place at the Hilton Garden Inn Florence Novoli in Florence, Italy on March 9, 2024. The company thanks in advance all the speakers and brand partners who will be attending this event. SIBIONICS looks forward to continuing the conversation and pushing the boundaries of CGM system innovation in its future events.

If the event piques your curiosity, don’t hesitate to contact the SIBIONICS public relations team in zy.zhang@sibionics.com

Author

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the launch of UDENYCA ONBODY™, the company’s on-body injector (OBI) presentation of UDENYCA® (pegfilgrastim-cbqv), is successfully underway, with a broad distribution of accounts nationwide ordering this innovative device, and patients now accessing its benefits. UDENYCA is a pegfilgrastim biosimilar administered the day after chemotherapy […]
"UDENYCA ONBODY Launch"

Subscribe Now